Anthropic reports early results from drug development partnerships
Work with six organisations, including Bristol Myers Squibb and Generate Biomedicines, ranges from redesigning part of a CAR-T therapy to drafting regulatory documents.
Source published · In the Daily Brief of 28 October 2026
Filed under AI industry, Agents
Anthropic said its life sciences team has spent several months working with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group, and has started drug discovery programmes of its own, including for rare childhood forms of muscular dystrophy.
At Generate Biomedicines, scientists using Claude Code proposed a version of one component of a CAR-T therapy about 70% shorter than the standard one; in lab tests it let immune cells make roughly 10 times as many receptors. For Divergence Labs, Claude generated roughly 35,000 antibody designs in about a month for a food-allergy programme. BigHat made and tested about 1,010 variants proposed with Claude in about 10 weeks, and the best bound more than 10 times more tightly than the originals. At Enveda, Claude caught all 11 issues human reviewers found in 1,061 pages of manufacturing records, flagged seven more, and cut review time by 89%.
The partners have published technical reports. Anthropic said it plans to scale the work up and to expand the clinical trial planning work with Bristol Myers Squibb in 2027.